Finally, future clinical trials will be required to establish the utility of LAT1 as a biomarker for breast cancer prognosis, particularly in association with other clinical factors: survival data in the datasets analyzed were limited, but will be important to examine in forthcoming studies. This evidence concerns the gene SLC7A5 and breast cancer.